ABL1 R351W

CI-VAR-00003835Explore in graph →NP_009297.2:p.Arg351TrpNM_007313.2:c.1051C>TCIViC 1656 rs779478267

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma2
ABL1 R351W	Dasatinib	Predictive	D	Supports Sensitivity Response	4	accepted	EID4787 In this in vitro study, the H1915 non-small cell lung cancer cell line (homozygous for a R351W mutation) was shown to be susceptible to dasatinib. This line showed a significant reduction in colony fo… (full text at CIViC) PMID 26758680 · Testoni et al., 2016 · Open in CIViC	civic
ABL1 R351W	Imatinib	Predictive	D	Supports Sensitivity Response	5	accepted	EID6376 In this in vitro study, the H1915 non-small cell lung cancer cell line (homozygous for a R351W mutation) was shown to be susceptible to imatinib. This line showed a significant reduction in colony for… (full text at CIViC) PMID 26758680 · Testoni et al., 2016 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.